Kentucky-based Aristides Capital has fully exited its position in the iShares Biotechnology ETF (NASDAQ: IBB), as reported in a November 13 SEC filing. The firm sold all 28,467 shares it held, with the estimated transaction value around $3.60 million, effectively liquidating its stake in the fund. This move significantly reduced Aristides Capital’s portfolio. Details on top holdings following this transaction were not disclosed in the filing.
